Appili set to evaluate favipiravir as preventive measure against Covid-19

This article was originally published here

The Canadian biopharma company expects to immediately begin recruitment for the mid-stage trial of favipiravir with an aim to enroll nearly 760 subjects from both residents and staff

The post Appili set to evaluate favipiravir as preventive measure against Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply